By Stephen Nakrosis
Genomic medicine company Sangamo Therapeutics said it entered a license agreement with Eli Lilly, under which Lilly received rights to employ Sangamo's proprietary capsid, STAC-BBB, for up to five potential disease targets.
Under the terms of the deal, Lilly is granted world-wide exclusive license to utilize STAC-BBB for one initial target, and has the right to add up to four additional targets after paying additional licensed target fees.
The deal will see Sangamo receive $18 million as an upfront license fee. Under the terms of the agreement, Sangamo is eligible to receive up to $1.4 billion in additional license fees, milestone payments and tiered royalties, the companies said.
Sangamo is responsible for completing a technology transfer related to STAC-BBB, while Lilly is responsible for all research, preclinical and clinical development, regulatory interactions, manufacturing, and global commercialization of any resulting gene therapy products, the companies said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 03, 2025 16:30 ET (20:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.